IRVINE, Calif.--(BUSINESS WIRE)--June 8, 2006--Cortex Pharmaceuticals, Inc. (AMEX: COR - News) announced that it has provided to the U.S. Food and Drug Administration the preclinical research plan for removal of the current clinical hold on AMPAKINE® CX717. The FDA recently provided a written response finding the proposed research plan to be acceptable. Both parties felt that the clarity of the proposed actions was sufficient such that a scheduled conference call for June 9, 2006 was no longer necessary.
